Endpoints
The primary endpoint of this study was to assess the protective effect of benralizumab and mepolizumab against the AHR elicited by histamine in hyperresponsive human bronchi.
The secondary endpoints included the impact of benralizumab and mepolizumab against the AHR elicited by EFS and mechanical stress induced by quick stretch (QS), and the effect of these mAbs on the modulation of cAMP levels in hyperrespnsive bronchial tissue.